US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

For the week ending Jan. 25, seasonal flu activity remains high and increasing. Clinical laboratories tested 129,378 ...

Nirsevimab is protective against RSV infections and coinfections, which suggests there is no replacement of RSV with other viruses post-nirsevimab administration.

In the wake of multiple cases of human metapneumovirus (hMPV) in India, multiple questions about its causes and symptoms seem ...

Inhalon Biopharma's inhaled RSV antibody treatment will enter human trials marking a potential breakthrough in respiratory ...

As we head into the peak of 2025 RSV season, parents are once again facing an uptick in cases, with health experts warning ...

At the start of every week, our team talks with local experts to unpack a wide range of nationwide health, safety, and ...